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Summary: Serum and ascitic ﬂ  uid superoxide dismutase (SOD) and malondialdehyde (MDA) levels were measured in 
43 patients with cirrhosis and in a 10 healthy control group.
Compensated cirrhotic patients had no clinically detectable ascites, but decompensated patients had massive ascites. 
Cirrhotic patients were divided into three groups: patients with compensated cirrhosis (n = 16), patients with decompensated 
cirrhosis with Spontaneous bacterial peritonitis (SBP) (n = 14), and patients with decompensated cirrhosis without SBP 
(n = 13).
All cirrhotic patients in the experimental group had signiﬁ  cantly higher serum SOD (p  0.001) and MDA levels (p  0.01) 
than those in the control group. There were no signiﬁ  cant differences with respect to serum SOD and MDA levels among 
the three different groups of patients. There was no remarkable difference in ascitic ﬂ  uid SOD and MDA levels between 
decompensated cirrhotic patients with and without SBP (p  0.05).
These results suggest that the increase in serum SOD and MDA levels are not related to the presence of SBP and the status 
of liver cirrhosis. To sum up, clarifying the impact of increased serum SOD and MDA levels in cirrhotic patients needs 
further investigation.
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Introduction
It has been reported that the superoxide anion radical and its scavenger, SOD, play an important role 
in many diseases, such as: anemia, malignant lymphoma and infectious diseases (Abou-Seif Mam et al. 
2000; Dias-Da-Motta et al. 1996; Liu et al. 1993, Pasguier et al. 1984). Increased production of free 
radicals plays an important role in the pathogenesis of liver disease and ﬁ  brosis (Ljubuncic et al. 2000; 
Nalini et al. 1999; Özenirler et al. 1994; Togashi et al. 1999). On the other hand, a lipid peroxidation 
product, MDA, affects lipocytes (Ito cells) directly or indirectly through the promotion of ﬁ  brogenesis 
in the liver (Friedman, 1999; Svegliati-Baroni et al. 1999; Sukamato et al. 1993). Many clinical studies, 
revealed the fact that MDA, which is a lipid peroxidation product, increases in various liver diseases 
(Paradis et al. 1997). These ﬁ  ndings point out the importance of MDA in the progession of Liver cirrhosis 
(LC). Moreover, little is known about the importance of SOD in LC, and the studies dealing with these 
results are controversial. According to our knowledge, there is no published report regarding the impor-
tance of ascitic ﬂ  uid SOD and MDA with and without SBP in patients with LC. The aim of the this 
study is to evaluate serum and ascitic ﬂ  uid SOD and MDA levels, and to determine whether the pres-
ence of SBP and the status of LC have any effect on serum and ascitic ﬂ  uid SOD and MDA levels in 
cirrhotic patients.
Materials and Methods
Forty-three patients (32 men and 11 women, mean age: 48 ± 3 years) with cirrhosis and a 10 healthy 
control group (5 men and 5 women, mean age: 47.4 ± 7.7 years) were included in this study. The study 
was conducted between 1999 and 2000. Liver cirrhosis was proven histologically in 14 cases and diag-
nosed on the basis of clinical, biochemical, imaging methods (ultrasound, CT) and endoscopic signs in 
other patients because of bleeding risk. Cirrhosis was related to post-hepatitis B in 16 patients, chronic 
alcohol intake in 14 patients, post-hepatitis C in 8 patients and cryptogenic cirrhosis in 5 patients. The 
severity of the disease was evaluated according to the Child-Pugh (Pugh et al.1973) classiﬁ  cation. 142
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Patients with congestive heart failure, renal failure 
(plasma urea 15 mmol/l and creatinine 150 μmol/l), 
lung disease, malignancy, hepatic encephalopathy 
or gastrointestinal bleeding were excluded. Diuretic 
and antibiotic therapy were stopped during the two 
weeks before the study. Serum total bilirubin, 
alanine amino transferase (ALT), albumin, gamma 
glutamyl transferase (GGT) and prothrombine time 
(PT) were measured in all of the patients. Charac-
teristics of patients and control subjects are shown 
in Table 1.
Serum and ascitic ﬂ  uid SOD and MDA levels 
were measured in 43 patients with cirrhosis and a 
10 healthy control group. Serum and ascitic ﬂ  uid 
samples were obtained from the patients and serum 
samples were obtained from the control subjects 
after overnight fasting. Compensated cirrhotic 
patients had no clinically detectable ascites but 
decompensated patients had massive ascites. 
Patients were divided into three groups: patients 
with compensated cirrhosis (n = 16), patients with 
decompensated cirrhosis and SBP, as deﬁ  ned by 
a polymorphonuclear cell count in ascitic ﬂ  uid 
of 250,000/ml and/or a positive culture associ-
ated with a clinical sign of SBP (n = 14), and 
patients with decompensated cirrhosis without SBP 
(n = 13). Cultures and polymorphonuclear cell 
counts were performed on the ascitic ﬂ  uid. Seven 
out of 14 cases of SBP had positive cultures (three 
Escherichia coli, two Bacteroides fragilis, one 
Enterococcus faecalis and one Staphyolococcus 
aureus). The remaining cases were deﬁ  ned by a 
polymorphonuclear cell count in ascitic fluid 
of 250,000/ml.
SOD measurement: The whole blood and ascitic 
fluid were centrifuged and blood serum was 
carefully separated. We treated the samples with 
chloroform and ethanol. and after centrifugation, 
0.5 ml supernatant was used for the assay. This 
assay for superoxide dismutase activitiy involves 
xanthine oxidase which was used as superoxide 
generator. One unit SOD is deﬁ  ned as the amount 
of the protein that inhibitis the rate of NBT reduction 
by 50% (IU/ml) (Sun et al. 1988).
Malondialdehyde measurement: The levels of 
malondialdehyde were determined in serum and 
ascitic ﬂ  uid of patients using the thiobarbituric acid 
method. The results were obtained in mol/ml. 
(Yoshioka et al. 1979).
The results are presented as mean  ±SD. The 
differences in results between patients and control 
subjects were compared using the Krushal-Wallis 
test. The Mann-Whitney ‘U’ test was used for 
intragroup comparisons. The Pearson test was used 
for correlation analysis. The signiﬁ  cance was taken 
at p  0.05.
Results
There were no signiﬁ  cant differences between the 
three groups of cirrhotic patients and control sub-
jects in terms of age, sex and pathogenesis of cir-
rhosis (Table 1). All cirrhotic patients showed 
signiﬁ  cant increases in serum SOD (p  0.001) 
and MDA (p  0.05) levels in comparison with 
those of control subjects . No signiﬁ  cant difference 
was found among the different groups of patients 
in terms of serum SOD and MDA levels (Table 2). 
Ascitic ﬂ  uid SOD and MDA levels were not dif-
ferent between decompensated cirrhotic patients 
with and without SBP (Table 3). Serum ALT levels 
were not different among three groups of patients. 
Serum total bilirubin levels were found to be lower 
in patients with compensated cirrhosis than those 
in patients with decompensated cirrhosis without 
SBP. Serum albumin levels were found to be higher 
Table 1. Characteristics of the patients.
Patients n Sex
(M/F)
Age
(year)
Ascites SBP* **CC
(A/B/C)
Etiology
HB/CA/HC/CR***
Controls 10 6/4 47 ± 7 No −− −
Patients with compensated 
cirrhosis
16 13/3 45 ± 13 No −  14/2/0 6/5/2/3
Patients with decompensated 
cirrhosis with SBP
14 10/4 46 ± 9 Severe + 0/1/13 5/5/3/1
Patients with decompensated 
cirrhosis without SBP
13 9/4 45 ± 10 Severe _ 0/2/11 5/4/3/1
*SBP: Spontaneous bacterial peritonitis, **CC: child-pugh classiﬁ  cation, ***HB: Hepatitis B; CA: chronic alcholism; HC: hepatitis C; 
CR: cryptogenic.143
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in patients with compensated cirrhosis than in other 
patients . Serum PT measurements were found to 
be lower in patients with compensated cirrhosis 
than in other patients (p  0.001). There was no 
diffference in serum ALT, albumin, total bilirubin 
levels and PT measurements of decompensated 
patients in terms of the SBP. Serum GGT levels 
were found to be lower in patients with decompen-
sated cirrhosis and SBP than in other patients 
(Table 4).
Discussion
In our study, we measured serum and ascitic ﬂ  uid 
SOD and MDA levels in patients with LC and 
serum SOD and MDA levels in control subjects to 
investigate the effect of severity of liver damage 
and SBP on these levels.
The results of several reports regarding the 
evaluation of serum SOD in patients with various 
forms of liver diseases are controversial (Makarenko 
et al. 1989; Zhurkin et al. 1989; Yasuyama et al. 
1988; Irshad et al. 1988).
Increased SOD levels were found by Maka-
renko et al. (1989) in persistent and active hepati-
tis or cirrhotic patients. They explained the increase 
in SOD as an adaptive reaction directed to the 
prevention of lipid peroxidation intensiﬁ  cation and 
its injurious effect on the cellular structures.
Similar results for patients with acute and 
chronic viral hepatitis were shown by Zhurkin et al. 
(1989), who explained SOD activation in red blood 
cells by enzyme induction with the superoxide 
anion radical.
Yasuyama et al. (1988) found significantly 
higher plasma SOD activity in chronic hepatitis, 
autoimmune hepatitis, primary biliary cirrhosis and 
hepatocellular carcinoma groups than in the healthy 
control group. They explained the increased activ-
ity of SOD by increased release of injured hepa-
tocytes.
In our study, we found results similar to 
Yasuyama et al. All cirrhotic patients had signiﬁ  -
canthy higher serum SOD and MDA levels than 
the control group. On the other hand, in serum and 
ascites, there are many kinds of substances, such as 
albumin, vitamin C and E, bilirubin or uric acid as 
well as SOD itself, that can scavenge superoxide 
radicals. In our study, we could not eliminate the 
effects of these SOD mimetic substances on our 
results by using our method (Inci et al. 2003; Kato 
et al. 2003). However, we think that SOD mimetic 
factors may have same effect on both control sub-
jects and patients.
Hadi et al. (1999) found lower activities of SOD 
in the erythrocytes obtained from patients with 
cirrhosis compared with those obtained from 
control subjects. They concluded that although the 
Table 2. Serum SOD and MDA levels of healthy controls and cirrhotic patients.
Patients n Serum SOD levels (IU/ml)
(mean ± SD)
Serum MDA levels (nmol/ml)
(mean ± SD)
Controls 10 0.395 ± 0.41*   7.95 ± 2.19**
Patients with compensated
cirrhosis
16 4.38 ± 2.03   15.1 ± 6.2
Patients with decompensated 
cirrhosis with SBP
14 3.71 ± 1.08 14.25 ± 6.3
Patients with decompensated 
cirrhosis without SBP
13 4.69 ± 1.95 16.41 ± 8.94
*p  0.001, **p  0.05.
Table 3. Ascitic ﬂ  uid SOD and MDA levels of cirrhotic patients with and without SBP.
Patients n Ascites SOD levels (IU/ml)
(mean ± SD)
Ascites MDA levels (nmol/ml)
(mean ± SD)
Patients with decompensated
cirrhosis with SBP
14 2.21 ± 1.34 9.96 ± 4.43
Patients with decompensated
cirrhosis without SBP
13 2.56 ± 1.00 7.65 ± 2.81144
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enzymatic antioxidant defense system is signiﬁ  cantly 
reduced in erythrocytes obtained from cirrhotic 
patients, this did not lead to further peroxidative 
reactions in the erythrocytes, possibly due to 
peroxidation of some cellular structures sensitive 
to peroxidative attack.
There was, however, an important indication of 
accelerated peroxidative reaction in the plasma of 
the cirrhotic patients, which possibly resulted from 
extracellular oxidant stress in these patients.
Chen et al. (1997) found that the blood levels 
of superoxide in decompensated cirrhotic patients 
were greater than in healthy controls or compen-
sated cirrhotic patients. They concluded that the 
increase in blood levels of superoxide in decom-
pensated cirrhotic patients is related to the impair-
ment of liver function.
Our results were not compatible with these 
studies. Our study scored the degree of liver sever-
ity according to the classiﬁ  cation of Child-Pugh. 
As seen in Table 1, most of patients had Child A 
disease in compensated patients, while patients 
with decompensated cirrhosis had predominantly 
Child C disease. We found no difference in serum 
levels of SOD and MDA among these three groups 
of patients. Moreover, we could not ﬁ  nd any cor-
relation between these levels and liver function 
tests including serum levels of GGT, ALT, total 
bilirubin, albumin and PT measurement among the 
groups. Our results did not conﬁ  rm the relationship 
or causality between serum SOD and MDA levels 
and the status of liver cirrhosis by using Child-
Pugh Score system.
We also investigated whether the presence of 
SBP has any effect on serum SOD and MDA lev-
els. However, serum SOD and MDA levels were 
found not to be signiﬁ  cantly different in patients 
with and without SBP.
Our study showed that it is not only the serum 
levels but also the ascitic ﬂ  uid SOD and MDA levels 
that turned out not to be different in decompensated 
cirrhotic patients with or without SBP. It was not 
compatible with the results of other studies regarding 
peritonitis and inﬂ  ammation (Goode and Webster, 
1993; Konukoğlu et al. 1999).
In conclusion, we found signiﬁ  cantly higher 
serum SOD and MDA levels in all cirrhotic patients 
than in the controls. On the other hand, high levels 
of serum SOD and MDA do not seem to be associ-
ated with the presence of SBP and compensation 
of liver cirrhosis. Moreover, we could not ﬁ  nd any 
correlation between these levels and liver function 
tests. Further studies are needed to explain the 
mechanism of this increase in serum SOD and 
MDA levels in cirrhosis.
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